BELITE BIO, INC (BLTE) Stock Price, Financials & Summary

Price chart

Oct 7Oct 12Oct 15Oct 20Oct 23Oct 28Nov 2Nov 5

Key dataNov 5, 2026

Open$152.50

From 52W high−26.04%

Volume223382.00

Market cap$5.77B

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataNov 5, 2026

Open

$152.50

From 52W high

−26.04%

Volume

223382.00

Market cap

$5.77B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−50.5x

P/E (TTM)

—

RSI (14)

39.7

MomentumView details →

1D Return

−7.03%

YTD Return

−9.88%

SummaryUpdated Jun 1, 2026

Belite Bio, Inc (NASDAQ:BLTE) is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in San Diego, California. The company operates as a subsidiary of Lin Bioscience International Ltd and went public in April 2022. Belite Bio specializes in developing novel oral therapeutics for rare retinal diseases, particularly focusing on conditions that cause progressive vision loss and blindness. The company's primary focus is on advancing treatments for Stargardt disease and geographic atrophy, two debilitating eye conditions that currently have limited or no approved treatment options.

Ask drillr about BELITE BIO, INC →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−50.5x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

7.4x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−13.18%

ROA (TTM)

−12.93%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

−79.22%

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

−95.76%

EBITDA YoY

—

MomentumView details →

1D Return

−7.03%

YTD Return

−9.88%

1Y Return

+29.02%

RSI (14)

39.7

vs 50D SMA

−10.35%

vs 200D SMA

−10.05%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

33.56x

Quick Ratio

33.56x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.70

EPS Surprise

4.11%

Beats (12Q)

3/12

Next Q EPS Est

−$0.91

Avg Surprise (4Q)

7.52%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−102.36M

Op. CF (TTM)

−10385.00

Next earningsNov 12, 2026 →

Latest newsMore news →

BELITE BIO, INC announced that it will host a webcast on November 12, 2026, to discuss its third-quarter financial results and provide a business update.20h ago

BELITE BIO, INC announced that it submitted marketing authorization applications for tinlarebant to regulatory authorities in Singapore, the United Kingdom and Switzerland for Stargardt disease type 1.23d ago

Similar companies

CG Oncology, Inc. Common stockCGON Kodiak Sciences Inc.KOD 博拓生物688767.SH Immunovant, Inc.IMVT Ligand Pharmaceuticals IncorporatedLGND Scholar Rock Holding CorporationSRRK Find similar companies →

Latest newsMore news →

BELITE BIO, INC announced that it will host a webcast on November 12, 2026, to discuss its third-quarter financial results and provide a business update.20h ago BELITE BIO, INC announced that it submitted marketing authorization applications for tinlarebant to regulatory authorities in Singapore, the United Kingdom and Switzerland for Stargardt disease type 1.23d ago